One-third of HER2-positive (HER2+) tumors express the P95HER2 protein, which associates with an aggressive form of breast ...
One-third of HER2-positive (HER2+) tumors express the P95HER2 protein, which associates with an aggressive form of breast ...
Ziihera is the first dual HER2-targeted bispecific antibody approved in the U.S. for HER2-positive biliary tract cancer ...
T therapy targeting p95HER2 shows complete and durable tumor responses in HER2+ breast cancer preclinical models. Combining ...
The new drug, Jazz Pharmaceuticals’ zanidatamab, has won an FDA accelerated approval for adults with previously treated ...
Zanidatamab is the first agent approved specifically for advanced, HER2-positive second-line biliary tract cancer.
Human epidermal growth factor receptor 2 (HER2) proteins are found on the surface of breast cells and are involved in normal cell growth. Too much HER2 protein, however, can cause some types of breast ...